$GWTI
Greenway Technologies Inc

2024 Q1 Form 10-Q Financial Statement

#000149315224030518 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $202.3K $330.0K
YoY Change -38.68% 38.66%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $202.3K $330.6K
YoY Change -38.8% 30.15%
Operating Profit -$202.3K -$330.6K
YoY Change -38.8% 30.15%
Interest Expense -$154.7K -$150.0K
YoY Change 3.15% 1.63%
% of Operating Profit
Other Income/Expense, Net -$154.7K -$153.1K
YoY Change 1.05% 3.74%
Pretax Income -$357.1K -$480.0K
YoY Change -25.61% 19.52%
Income Tax
% Of Pretax Income
Net Earnings -$357.1K -$483.7K
YoY Change -26.18% 20.45%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 403.8M shares 388.5M shares
Diluted Shares Outstanding 403.8M shares 388.5M shares

Balance Sheet

Concept 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change -100.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $0.00
YoY Change -100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets $0.00 $0.00
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.727M $7.433M
YoY Change 17.42% 987.9%
Accrued Expenses $4.943M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $652.5K $657.5K
YoY Change -0.76%
Long-Term Debt Due $2.972M $2.972M
YoY Change 0.0% -17.84%
Total Short-Term Liabilities $12.39M $11.07M
YoY Change 11.93% 8.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $12.39M $11.07M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $12.39M $11.07M
YoY Change 11.93% 8.3%
SHAREHOLDERS EQUITY
Retained Earnings -$38.22M -$36.76M
YoY Change 3.96%
Common Stock $25.83M $25.70M
YoY Change 0.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.39M -$11.07M
YoY Change
Total Liabilities & Shareholders Equity
YoY Change

Cashflow Statement

Concept 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$357.1K -$483.7K
YoY Change -26.18% 20.45%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.782K -$144.8K
YoY Change -98.77% 36.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $135.0K
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $650.00 $120.2K
YoY Change -99.46% 163.02%
NET CHANGE
Cash From Operating Activities -$1.782K -$144.8K
Cash From Investing Activities
Cash From Financing Activities $650.00 $120.2K
Net Change In Cash -$1.132K -$24.60K
YoY Change -95.4% -59.06%
FREE CASH FLOW
Cash From Operating Activities -$1.782K -$144.8K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0893594
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1521 North Cooper Street
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Arlington
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
76011
CY2024Q1 dei City Area Code
CityAreaCode
(561)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
809-4644
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001572386
CY2024Q1 us-gaap Cash
Cash
usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
usd
CY2024Q1 us-gaap Assets
Assets
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
usd
CY2023Q1 GWTI Stock Issued During Period Value Issuance Of Previously Issuable Shares
StockIssuedDuringPeriodValueIssuanceOfPreviouslyIssuableShares
usd
CY2024Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
usd
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2024Q1 us-gaap Stock Issued1
StockIssued1
usd
CY2024Q1 us-gaap Cash
Cash
usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-55030
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
GREENWAY TECHNOLOGIES, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
TX
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.0001
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
416289538 shares
CY2024Q1 GWTI Convertible Note Payable Current
ConvertibleNotePayableCurrent
166667 usd
CY2023Q4 GWTI Convertible Note Payable Current
ConvertibleNotePayableCurrent
166667 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12386382 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
403844204 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
403844204 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
403844204 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
403844204 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
40385 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
25789908 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38216675 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-12386382 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
202338 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
202338 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-202338 usd
CY2024Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
154733 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-154733 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-357071 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
403844204 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
403844204 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
388477538 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
388477538 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-12029311 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-357071 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-12386382 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10737576 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10737576 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
20000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
135000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-483719 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-11066295 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-11066295 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-357071 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-483719 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
20000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2947 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
156825 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
155871 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
198464 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
160106 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1782 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-144795 usd
CY2024Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
650 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
200 usd
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
15000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
650 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
120200 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1132 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24595 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1132 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24595 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
5000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-357071 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1782 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38216675 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-12386382 usd
CY2024Q1 GWTI Working Capital Deficit
WorkingCapitalDeficit
12386382 usd
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zY6Gj9t02xec" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zzHbx7vatlK6">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates, and those estimates may be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and other assumptions, which include both quantitative and qualitative assessments that it believes to be reasonable under the circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates during the three months ended March 31, 2024 and 2023, respectively, include valuation of stock-based compensation, uncertain tax positions, and the valuation allowance on deferred tax assets.</span></p>
CY2024Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2024Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2024Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
4157888 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3781863 shares
CY2024Q1 GWTI Notes Issuance Date
NotesIssuanceDate
Various
CY2024Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P1Y
CY2024Q1 us-gaap Debt Instrument Collateral
DebtInstrumentCollateral
All assets
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Voting at 1 vote per share
CY2024Q1 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
2137627 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4943401 usd

Files In Submission

Name View Source Status
0001493152-24-030518-index-headers.html Edgar Link pending
0001493152-24-030518-index.html Edgar Link pending
0001493152-24-030518.txt Edgar Link pending
0001493152-24-030518-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
ex32-3.htm Edgar Link pending
ex32-3_001.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
gwti-20240331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
gwti-20240331_cal.xml Edgar Link unprocessable
gwti-20240331_lab.xml Edgar Link unprocessable
gwti-20240331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
gwti-20240331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable